Following a high-energy Capital Markets Day, SynAct Pharma’s CSO and founder, Thomas Jonassen, joins us to discuss the roadmap for a transformational 2026. With upcoming Phase 2b data for the ADVANCE (RA) study in Q2, followed by a period of intense value creation through two other major clinical readouts. It is a truly exciting time for the company.

Läs mer på Redeye

Ämnen i artikeln


SynAct Pharma

Senast

17,38

1 dag %

−0,80%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån